Literature DB >> 32091301

EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance.

Zehra Tavsan1,2, Hülya Ayar Kayalı2,3,4.   

Abstract

Alterations of cell adhesion are involved in cancer progression, but the mechanisms underlying the progression and cell adhesion have remained poorly understood. Focusing on the complex between EpCAM, claudins and tetraspanins, we described a sequence of events by which of the molecules associate each other in ovarian cancer. The interactions between molecules were evaluated by immunoprecipitations and then immunoblotting. To identify the effects of complex formation on the ovarian cancer progression, the different types of ovarian cancer cell lines were compared. In this study, we report the identification of the EpCAM-claudin-4 or -7-CD82 complex in the ovarian cancer progression and metastasis in vitro. Additionally, we demonstrated palmitoylation and intra- or extra-cellular regions are critically required for the complex formation. These results represent the first direct evidence for the link between the dynamism of cell adhesion molecules and ovarian cancer progression.

Entities:  

Keywords:  EpCAM; Ovarian cancer; cell adhesion; claudins; palmitoylation; tetraspanins

Mesh:

Substances:

Year:  2020        PMID: 32091301      PMCID: PMC7757826          DOI: 10.1080/19336918.2020.1732761

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  44 in total

1.  Downregulation of KAI1 metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer.

Authors:  M Schindl; P Birner; G Breitenecker; G Oberhuber
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

Review 2.  Cell polarity in development and cancer.

Authors:  Andreas Wodarz; Inke Näthke
Journal:  Nat Cell Biol       Date:  2007-09       Impact factor: 28.824

3.  Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity.

Authors:  Rachana Agarwal; Theresa D'Souza; Patrice J Morin
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

4.  Palmitoylation and intracellular domain interactions both contribute to raft targeting of linker for activation of T cells.

Authors:  Hidehiko Shogomori; Adam T Hammond; Anne G Ostermeyer-Fay; Daniel J Barr; Gerald W Feigenson; Erwin London; Deborah A Brown
Journal:  J Biol Chem       Date:  2005-03-07       Impact factor: 5.157

5.  Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression.

Authors:  Christopher D Houle; Xiao-Yu Ding; Julie F Foley; Cynthia A Afshari; J Carl Barrett; Barbara J Davis
Journal:  Gynecol Oncol       Date:  2002-07       Impact factor: 5.482

6.  CD44 variant isoforms associate with tetraspanins and EpCAM.

Authors:  Dirk-Steffen Schmidt; Pamela Klingbeil; Martina Schnölzer; Margot Zöller
Journal:  Exp Cell Res       Date:  2004-07-15       Impact factor: 3.905

7.  Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.

Authors:  Karen H Lu; Andrea P Patterson; Lin Wang; Rebecca T Marquez; Edward N Atkinson; Keith A Baggerly; Lance R Ramoth; Daniel G Rosen; Jinsong Liu; Ingegerd Hellstrom; David Smith; Lynn Hartmann; David Fishman; Andrew Berchuck; Rosemarie Schmandt; Regina Whitaker; David M Gershenson; Gordon B Mills; Robert C Bast
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

8.  Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma.

Authors:  S Uchida; Y Shimada; G Watanabe; Z G Li; T Hong; M Miyake; M Imamura
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

9.  CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling.

Authors:  Lauren A Baldwin; John T Hoff; Jason Lefringhouse; Michael Zhang; Changhe Jia; Zeyi Liu; Sonia Erfani; Hongyan Jin; Mei Xu; Qing-Bai She; John R van Nagell; Chi Wang; Li Chen; Rina Plattner; David M Kaetzel; Jia Luo; Michael Lu; Dava West; Chunming Liu; Fred R Ueland; Ronny Drapkin; Binhua P Zhou; Xiuwei H Yang
Journal:  Oncotarget       Date:  2014-12-15

10.  The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.

Authors:  Shingo Tayama; Takeshi Motohara; Dashdemberel Narantuya; Chenyan Li; Koichi Fujimoto; Isao Sakaguchi; Hironori Tashiro; Hideyuki Saya; Osamu Nagano; Hidetaka Katabuchi
Journal:  Oncotarget       Date:  2017-07-04
View more
  3 in total

1.  Establishment of an optimized CTC detection model consisting of EpCAM, MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics.

Authors:  Tongxia Wang; Yan Gao; Xi Wang; Junrui Tian; Yuan Li; Bo Yu; Cuiyu Huang; Hui Li; Huamao Liang; David M Irwin; Huanran Tan; Hongyan Guo
Journal:  Chin J Cancer Res       Date:  2022-04-30       Impact factor: 4.026

2.  Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer.

Authors:  Lin Zhao; Yuhui Li; Zhen Zhang; Jing Zou; Jianfu Li; Ran Wei; Qiang Guo; Xiaoxiao Zhu; Chu Chu; Xiaoxiao Fu; Jinbo Yue; Xia Li
Journal:  Biosci Rep       Date:  2020-11-27       Impact factor: 3.840

3.  Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis.

Authors:  Kelly Pedrozo Ferreira; Bruna Cristine de Almeida; Laura Gonzalez Dos Anjos; Glauco Baiocchi; Fernando Augusto Soares; Rafael Malagoli Rocha; Edmund Chada Baracat; Andrey Senos Dobroff; Katia Candido Carvalho
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.